All In Biotech

NDA 018895 · Hospira

Tpn Electrolytes In Plastic Container

Calcium Chloride, Magnesium Chloride, Potassium Chloride, Sodium Acetate, Sodium Chloride · Injection

Last checked: Nov 20, 2026Latest source record: Jun 12, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Jul 20, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9,299

2,122 Phase 3, 968 recruiting

FAERS reports

35

29 serious, 6 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 25, 2026.

INDICATIONS AND USAGE TPN Electrolytes (multiple electrolyte additive) is indicated for use as a supplement to nutritional solutions containing concentrated dextrose and amino acids delivered by central venous infusion, to help maintain electrolyte homeostasis in adult patients.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 20, 1984 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • TPN ELECTROLYTES IN PLASTIC CONTAINER · CALCIUM CHLORIDE 16.5MG/ML; MAGNESIUM CHLORIDE 25.4MG/ML; POTASSIUM CHLORIDE 74.6MG/ML; SODIUM ACETATE 121MG/ML; SODIUM CHLORIDE 16.1MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.

All 9,299 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea4
  • vomiting4
  • urticaria3
  • cough2
  • covid-192
  • death2
  • fungaemia2
  • hepatic failure2
  • pruritus2
  • sepsis2
  • urinary tract infection2
  • abdominal abscess1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20101
20121
20141
20153
20183
20194
20202
20214
20225
20233
20243
20251
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,091 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.